Chemotherapy With or Without Immunotherapy for Lung Cancer
Treatments studied
Part of Cancer, Lungs & breathing clinical trials.
This trial looks at whether adding an immunotherapy drug (an immune checkpoint inhibitor) to chemotherapy helps people with lung cancer live better or respond better. You might be considered if your cancer is confirmed, you can tolerate treatment, and imaging shows measurable spots.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older with lung cancer confirmed by a tissue biopsy
- Your cancer plan already includes chemotherapy, with or without an immunotherapy drug
- Your daily functioning is good (you can take care of yourself; ECOG 0–1)
- You are expected to live at least 12 more weeks
- Blood counts and major organs (heart, liver, kidneys) are working well enough for treatment
- Scans show at least one measurable tumor spot that can be followed (RECIST 1.1)
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether giving focused radiation to remaining spots of lung cancer (after standard treatment) can help prevent cancer from growing back. It may be an option if you have had 4-6 cycles of chemo plus immunotherapy and still have a few active spots.
This trial tests a combination of an immunotherapy drug (sintilimab) with chemotherapy to shrink advanced lung cancer that cannot be removed with surgery. The goal is to see if the cancer becomes operable after treatment and to improve outcomes.
This trial tests a combination of immunotherapy (tislelizumab), a targeted therapy (anlotinib), and standard chemotherapy before and after surgery for people with early-stage but high-risk lung cancer. The goal is to see if this treatment shrinks the tumor, makes surgery more effective, and helps prevent the cancer from coming back.
This trial tests whether giving a type of immunotherapy (sintilimab) along with chemotherapy before and after surgery to remove the main lung tumor can help people with advanced non-small cell lung cancer. The goal is to see if this approach improves outcomes compared to standard treatment.
This trial tests a new drug called cadonilimab combined with chemotherapy for people with advanced lung cancer who have already tried and failed immunotherapy. It aims to see if this combination can help when standard immunotherapy no longer works.
This trial tests a new combination of an immunotherapy drug (QL1706) with chemotherapy and a special radiation technique (Quad Shot) for people with advanced non-small cell lung cancer that has spread. The goal is to see if this combination can help control the cancer better than standard treatment.
Hear when a new Non Small Cell Lung Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.